Supernus Pharmaceuticals (SUPN) Other Non-Current Liabilities (2011 - 2026)

Supernus Pharmaceuticals has reported Other Non-Current Liabilities for 16 years, with the latest figure at $19.9 million in Q2 2026.

• Other Non-Current Liabilities for Q2 2026 came in at $19.9 million, up 156.02% year-over-year; the trailing twelve-month figure through Jun 2026 was $19.9 million (up 156.02% YoY), and the FY2025 annual result was $31.3 million, down 33.97% from the prior year.
• Other Non-Current Liabilities climbed to $19.9 million in Q2 2026, from $19.5 million in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $57.4 million in Q3 2022 and troughed at $7.8 million in Q2 2025.
• A 5-year average of $41.9 million and a median of $50.2 million in 2024 frame the typical range for Other Non-Current Liabilities.
• The widest annual swing landed in 2025, when Other Non-Current Liabilities slumped 83.83%; it then soared 156.02% in 2026.
• A 5-year view of Other Non-Current Liabilities shows it stood at $55.0 million in 2022, then retreated by 2.76% to $53.4 million in 2023, then declined by 11.43% to $47.3 million in 2024, then tumbled by 33.97% to $31.3 million in 2025, then tumbled by 36.43% to $19.9 million in 2026.
• Per Business Quant data, the three most recent Other Non-Current Liabilities figures were $19.9 million in Q2 2026, $19.5 million in Q1 2026, and $31.3 million in Q4 2025.